PDF(Pubmed)
Abstract：
The global spread of severe acute respiratory syndrome coronavirus 2 has resulted in a significant number of individuals developing pulmonary fibrosis (PF), an irreversible lung injury. This condition can manifest within a short interval following the onset of pneumonia symptoms, sometimes even within a few days. While lung transplantation is a potentially lifesaving procedure, its limited availability, high costs, intricate surgeries, and risk of immunological rejection present significant drawbacks. The optimal timing of medication administration for coronavirus disease 2019 (COVID-19)-induced PF remains controversial. Despite this, it is crucial to explore pharmacotherapy interventions, involving early and preventative treatment as well as pharmacotherapy options for advanced-stage PF. Additionally, studies have demonstrated disparities in anti-fibrotic treatment based on race and gender factors. Genetic mutations may also impact therapeutic efficacy. Enhancing research efforts on pharmacotherapy interventions, while considering relevant pharmacological factors and optimizing the timing and dosage of medication administration, will lead to enhanced, personalized, and fair treatment for individuals impacted by COVID-19-related PF. These measures are crucial in lessening the burden of the disease on healthcare systems and improving patients\' quality of life.
摘要：
严重急性呼吸系统综合症冠状病毒2的全球传播导致大量个体发展为肺纤维化(PF),不可逆的肺损伤.这种情况可以在肺炎症状发作后的短时间内表现出来，有时甚至在几天内。虽然肺移植是一种潜在的救命程序，其有限的可用性，高成本,复杂的手术,和免疫排斥的风险存在显著的缺点。2019年冠状病毒病（COVID-19）诱导的PF的最佳用药时机仍存在争议。尽管如此,探索药物治疗干预措施至关重要，涉及早期和预防性治疗以及晚期PF的药物治疗选择。此外,研究表明,基于种族和性别因素的抗纤维化治疗存在差异.基因突变也可能影响治疗效果。加强药物治疗干预的研究工作，同时考虑相关药理因素，优化用药时机和剂量，将导致增强，个性化，以及对受COVID-19相关PF影响的个人的公平待遇。这些措施对于减轻疾病对医疗保健系统的负担和改善患者的生活质量至关重要。
